Leerink Partnrs Analysts Raise Earnings Estimates for FATE

Key Points

• Fate Therapeutics has seen an increase in Q3 earnings per share (EPS) estimates from ($0.37) to ($0.28) as per Leerink Partners, with a full-year consensus estimate of ($1.63) EPS.
• The company reported a Q2 EPS of ($0.29), which exceeded the consensus estimate by $0.06, alongside revenues of $1.91 million against expectations of $1.16 million.
• Fate Therapeutics' stock currently has a consensus rating of "Hold" with an average price target of $3.30, following several downgrades in price targets from analysts.

Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Equities research analysts at Leerink Partnrs boosted their Q3 2025 EPS estimates for shares of Fate Therapeutics in a research note issued to investors on Wednesday, September 3rd. Leerink Partnrs analyst D. Graybosch now forecasts that the biopharmaceutical company will earn ($0.28) per share for the quarter, up from their prior estimate of ($0.37). The consensus estimate for Fate Therapeutics' current full-year earnings is ($1.63) per share. Leerink Partnrs also issued estimates for Fate Therapeutics' Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.13) EPS, FY2026 earnings at ($1.10) EPS, FY2027 earnings at ($1.18) EPS, FY2028 earnings at ($0.90) EPS and FY2029 earnings at ($0.82) EPS.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.06. Fate Therapeutics had a negative return on equity of 50.95% and a negative net margin of 2,025.05%.The business had revenue of $1.91 million during the quarter, compared to the consensus estimate of $1.16 million.

Several other equities research analysts have also weighed in on the stock. Wells Fargo & Company dropped their price objective on shares of Fate Therapeutics from $4.00 to $2.50 and set an "equal weight" rating on the stock in a research note on Wednesday, August 13th. Wall Street Zen raised shares of Fate Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, August 18th. Robert W. Baird cut their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set a "neutral" rating on the stock in a report on Wednesday, May 14th. Barclays lowered their price objective on Fate Therapeutics from $10.00 to $2.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th. Finally, Needham & Company LLC restated a "hold" rating on shares of Fate Therapeutics in a research note on Thursday, June 12th. One analyst has rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $3.30.

Fate Therapeutics Stock Performance

Shares of NASDAQ FATE traded up $0.05 during trading on Friday, reaching $1.03. The stock had a trading volume of 1,123,836 shares, compared to its average volume of 1,986,330. Fate Therapeutics has a one year low of $0.66 and a one year high of $4.20. The stock has a market cap of $118.21 million, a PE ratio of -0.71 and a beta of 2.21. The firm's 50 day moving average price is $1.10 and its two-hundred day moving average price is $1.10.

Institutional Trading of Fate Therapeutics

A number of institutional investors have recently made changes to their positions in FATE. Savant Capital LLC acquired a new stake in shares of Fate Therapeutics in the 2nd quarter worth approximately $27,000. Bridgeway Capital Management LLC acquired a new stake in shares of Fate Therapeutics in the 2nd quarter worth approximately $28,000. CWM LLC lifted its stake in shares of Fate Therapeutics by 899.6% in the 1st quarter. CWM LLC now owns 41,435 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 37,290 shares during the period. Graham Capital Management L.P. acquired a new stake in shares of Fate Therapeutics in the 4th quarter worth approximately $37,000. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of Fate Therapeutics in the 4th quarter worth approximately $41,000. 97.54% of the stock is owned by institutional investors and hedge funds.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.